Profile data is unavailable for this security.
About the company
PHAXIAM Therapeutics SA, formerly known as ERYTECH PHARMA SA, is a France-based biopharmaceutical company developing medicinal products mainly in oncology, hematology and immunology fields of business. The company relies on the use of phages, natural bacteria-killing viruses. PHAXIAM Therapeutics SA is developing a portfolio of phages targeting three of the most resistant and dangerous bacteria, which alone account for more than two-thirds of resistant nosocomial infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. It offers ESY-ASP (GRASPA), a medicinal product consisting of L-Asparaginase entrapped into human homologous red blood cells. The product is used for treatment of Acute Lymphoblastic Leukemia (ALL), a childhood cancer.
- Revenue in EUR (TTM)1.33m
- Net income in EUR-23.49m
- Incorporated2004
- Employees51.00
- LocationPhaxiam Therapeutics SA60 avenue RockefellerLYON 69008FranceFRA
- Phone+33 478744438
- Fax+33 478755629
- Websitehttps://erytech.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IntegraGen SA | 12.54m | -171.40k | 4.24m | 55.00 | -- | 2.07 | 158.08 | 0.338 | -0.025 | -0.025 | 1.90 | 0.3041 | 1.47 | 12.06 | 4.06 | 227,953.30 | -2.01 | -1.93 | -4.78 | -4.41 | 66.41 | 65.11 | -1.37 | -1.51 | 1.57 | -- | 0.3587 | -- | -4.78 | 12.61 | -4,783.19 | -- | -- | -- |
| Theranexus SA | 0.00 | -6.83m | 5.43m | 19.00 | -- | 2.44 | -- | -- | -1.09 | -1.09 | 0.00 | 0.2863 | 0.00 | -- | -- | 0.00 | -70.79 | -42.66 | -82.29 | -47.97 | -- | -- | -- | -- | -- | -1,058.68 | 0.6212 | -- | -- | -- | -3.97 | -- | -33.23 | -- |
| Quantum Genomics SA | 10.06k | -3.17m | 6.63m | 3.00 | -- | 7.59 | -- | 658.99 | -0.091 | -0.091 | 0.0003 | 0.0125 | 0.0007 | -- | 0.0016 | 3,353.33 | -23.14 | -60.77 | -95.19 | -102.24 | -14,205.07 | -3,548.91 | -31,520.38 | -3,374.13 | -- | -146.53 | 0.8615 | -- | -98.34 | -- | 87.28 | -- | -- | -- |
| Acticor Biotech SA | 0.00 | -18.64m | 7.56m | 28.00 | -- | -- | -- | -- | -1.55 | -1.55 | 0.00 | -0.4028 | 0.00 | -- | -- | 0.00 | -164.53 | -- | -568.29 | -- | -- | -- | -- | -- | -- | -19.85 | 10.47 | -- | -- | -- | -17.40 | -- | -- | -- |
| Plant Advanced Technologies PAT SA | 1.68m | 79.16k | 17.61m | 27.00 | 219.46 | 2.06 | 30.38 | 10.47 | 0.0725 | 0.0725 | 1.54 | 7.73 | 0.1118 | -0.4123 | 1.60 | 62,278.52 | 0.5262 | -3.53 | 0.6534 | -4.39 | 128.03 | 134.21 | 4.71 | -33.16 | 0.4183 | -15.32 | 0.3402 | -- | 8.56 | 8.05 | 119.67 | -38.00 | -- | -- |
| Phaxiam Therapeutics SA | 1.33m | -23.49m | 19.16m | 51.00 | -- | 0.4927 | -- | 14.45 | -5.14 | -5.14 | 0.2901 | 3.90 | 0.0273 | -- | 14.82 | 26,000.00 | -48.37 | -50.69 | -66.94 | -66.25 | -- | -- | -1,771.42 | -1,009.09 | -- | -70.21 | 0.3412 | -- | -80.05 | -21.50 | -10,201.75 | -- | -56.68 | -- |
| Oncodesign Precision Medicine Opm SA | 1.07m | -8.09m | 20.65m | 22.00 | -- | 5.12 | -- | 19.26 | -0.4863 | -0.4863 | 0.0645 | 0.2219 | 0.0613 | -- | 1.39 | 48,735.00 | -46.23 | -- | -63.87 | -- | 130.48 | -- | -754.61 | -- | -- | -- | 0.7052 | -- | -86.57 | -- | -3,399.73 | -- | -- | -- |
| Valbiotis SA | 4.73m | -7.37m | 21.26m | 52.00 | -- | 1.08 | -- | 4.49 | -0.5904 | -0.5904 | 0.3798 | 1.24 | 0.1564 | 3.36 | 17.83 | 91,019.23 | -24.35 | -32.92 | -33.77 | -46.36 | 48.76 | 53.15 | -155.67 | -418.87 | 3.38 | -38.19 | 0.2598 | -- | 502.93 | 126.73 | 40.16 | -- | -21.71 | -- |
| Predilife SA | 317.79k | -4.22m | 21.49m | 19.00 | -- | -- | -- | 67.62 | -1.14 | -1.14 | 0.0858 | -1.06 | 0.0695 | -- | 2.05 | 17,030.55 | -92.43 | -89.36 | -129.39 | -123.81 | 97.25 | 83.94 | -1,329.21 | -1,901.22 | -- | -6.23 | 2.20 | -- | 10.11 | 79.85 | -15.58 | -- | -18.51 | -- |
| Nfl Biosciences SAS | 0.00 | -3.48m | 21.64m | 3.00 | -- | 5.44 | -- | -- | -0.5396 | -0.5396 | 0.00 | 0.4097 | 0.00 | -- | -- | 0.00 | -80.79 | -- | -125.59 | -- | -- | -- | -- | -- | -- | -- | 0.0228 | -- | -- | -- | -149.78 | -- | -- | -- |
| Poxel SA | 1.55m | -44.24m | 28.49m | 30.00 | -- | -- | -- | 18.43 | -1.44 | -1.44 | 0.0507 | -1.22 | 0.0597 | -- | 5.42 | 30,920.00 | -170.71 | -31.97 | -432.50 | -55.94 | 0.1294 | -- | -2,861.58 | -101.47 | -- | -4.08 | 11.28 | -- | -94.97 | -33.77 | -32.13 | -- | -8.49 | -- |
Data as of Jul 26 2024. Currency figures normalised to Phaxiam Therapeutics SA's reporting currency: Euro EUR
2.02%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Armistice Capital LLCas of 31 Dec 2022 | 176.27k | 1.58% |
| OFI Invest Asset Management SAas of 29 Feb 2024 | 18.27k | 0.16% |
| BVF Partners LPas of 28 Mar 2023 | 10.53k | 0.10% |
| Generali Asset Management SGR SpAas of 30 Dec 2022 | 7.57k | 0.07% |
| Gestys SAas of 31 May 2024 | 4.33k | 0.04% |
| Friedland Gestion SASas of 22 Mar 2024 | 3.65k | 0.03% |
| BBVA Asset Management SA SGIICas of 31 Dec 2023 | 2.71k | 0.02% |
| Deka Investment GmbHas of 31 Dec 2023 | 942.00 | 0.01% |
| Montaigne Capital SASas of 30 Apr 2024 | 487.00 | 0.00% |
| DWS Investment GmbHas of 31 Dec 2022 | 0.00 | 0.00% |
More ▼
Data from 28 Mar 2024 - 28 Jun 2024Source: FactSet Research Systems Inc.
